Vaccines,
Год журнала:
2023,
Номер
11(4), С. 875 - 875
Опубликована: Апрель 20, 2023
Immunological
memory
is
the
key
source
of
protective
immunity
against
pathogens.
At
current
stage
COVID-19
pandemic,
heterologous
combinations
exposure
to
viral
antigens
during
infection
and/or
vaccination
shape
a
distinctive
immunological
memory.
Immune
imprinting,
downside
memory,
might
limit
generation
de
novo
immune
response
variant
or
next-generation
vaccines.
Here,
we
review
mechanistic
basis
imprinting
by
focusing
on
B
cell
immunobiology
and
discuss
extent
which
harmful,
as
well
its
effect
SARS-CoV-2
vaccination.
Science,
Год журнала:
2022,
Номер
378(6620), С. 619 - 627
Опубликована: Окт. 20, 2022
Severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
Omicron
sublineages
carry
distinct
spike
mutations
resulting
in
escape
from
antibodies
induced
by
previous
infection
or
vaccination.
We
show
that
hybrid
immunity
vaccine
boosters
elicit
plasma-neutralizing
against
BA.1,
BA.2,
BA.2.12.1,
and
BA.4/5,
breakthrough
infections,
but
not
vaccination
alone,
induce
neutralizing
the
nasal
mucosa.
Consistent
with
immunological
imprinting,
most
derived
memory
B
cells
plasma
of
cases
cross-react
Wuhan-Hu-1,
BA.4/5
receptor-binding
domains,
whereas
primary
infections
narrow
specificity
up
to
6
months
after
infection.
Although
clinical
have
reduced
neutralization
Omicron,
we
identified
an
ultrapotent
pan-variant–neutralizing
antibody
is
a
strong
candidate
for
development.
PLoS Pathogens,
Год журнала:
2022,
Номер
18(11), С. e1010951 - e1010951
Опубликована: Ноя. 18, 2022
SARS-CoV-2
continues
to
acquire
mutations
in
the
spike
receptor-binding
domain
(RBD)
that
impact
ACE2
receptor
binding,
folding
stability,
and
antibody
recognition.
Deep
mutational
scanning
prospectively
characterizes
impacts
of
on
these
biochemical
properties,
enabling
rapid
assessment
new
seen
during
viral
surveillance.
However,
effects
can
change
as
virus
evolves,
requiring
updated
deep
scans.
We
determined
all
single
amino
acid
Omicron
BA.1
BA.2
RBDs
ACE2-binding
affinity,
RBD
folding,
escape
from
binding
by
LY-CoV1404
(bebtelovimab)
monoclonal
antibody.
The
some
differ
those
measured
ancestral
Wuhan-Hu-1
background.
These
epistatic
shifts
largely
resemble
previously
Alpha
variant
due
convergent
epistatically
modifying
N501Y
substitution.
variants
show
additional
lineage-specific
shifts,
including
examples
phenomenon
entrenchment
causes
Q498R
substitutions
present
be
more
favorable
background
than
earlier
strains.
In
contrast,
substitution
Q493R
exhibits
no
sign
entrenchment,
with
derived
state,
R493,
being
unfavorable
for
Wuhan-Hu-1.
Likely
this
reason,
R493Q
reversion
has
occurred
sub-variants
BA.4/BA.5
BA.2.75,
where
affinity
buffer
may
potentiate
concurrent
antigenic
change.
Consistent
prior
studies,
we
find
have
reduced
expression,
identify
candidate
stabilizing
ameliorate
deficit.
Last,
our
maps
highlight
a
broadening
sites
compared
datasets
landscape
inform
ongoing
efforts
EBioMedicine,
Год журнала:
2022,
Номер
84, С. 104270 - 104270
Опубликована: Сен. 18, 2022
BackgroundGenetically
distinct
viral
variants
of
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
have
been
recorded
since
January
2020.
The
introduction
global
vaccine
programs
has
contributed
to
lower
COVID-19
hospitalisation
and
mortality
rates,
particularly
in
developed
countries.
In
late
2021,
Omicron
BA.1
emerged,
with
substantially
altered
genetic
differences
clinical
effects
from
other
concern.
Shortly
after
dominating
spread
early
2022,
was
supplanted
by
the
genetically
lineage
BA.2.
A
sub-lineage
BA.2,
designated
BA.5,
presently
an
outgrowth
advantage
over
BA.2
sub-lineages.
Here
we
study
neutralisation
BA.1,
BA.5
pre-Omicron
using
a
range
convalescent
sera
therapeutic
monoclonal
antibodies
live
virus
assay.
Using
primary
nasopharyngeal
swabs,
also
tested
relative
fitness
compared
lineages
their
ability
use
ACE2-TMPRSS2
pathway.MethodsUsing
low
passage
isolates
Clade
A.2.2,
Beta,
Delta,
determined
humoral
vitro
vaccinated
cohorts,
concentrated
human
IgG
pooled
thousands
plasma
donors,
licensed
antibody
therapies.
We
then
infectivity
particle
ratios
samples
expanded
engineered
ACE2/TMPRSS2
cell
line
presence
absence
TMPRSS2
inhibitor
Nafamostat.FindingsPeak
responses
3
doses
BNT162b2
were
associated
9-fold
reduction
for
BA.5.
Concentrated
donors
vaccination
breakthrough
infections
greater
breadth
neutralisation,
although
potency
still
reduced
7-fold
across
all
lineages.
Testing
grade
revealed
14.3-fold
Evusheld
16.8-fold
Sotrovimab
Whilst
attenuated
entry,
observed
be
equivalent
that
2020
circulating
clade
had
sensitivity
Nafamostat.InterpretationObservations
support
significantly
escape
neutralising
and/or
responses.
Potency
is
differs
key
difference
sub-variants
reversion
tropism
back
well-known
pathway,
utilised
efficiently
Monitoring
if
these
changes
influence
transmission
disease
severity
will
ongoing
tracking
management
waves
globally.FundingThis
work
primarily
supported
Australian
Medical
Foundation
research
grants
MRF2005760
(ST,
GM
&
WDR),
MRF2001684
(ADK
ST)
Research
Future
Fund
Antiviral
Development
Call
grant
(WDR),
(MRFF2001684,
ADK
SGT)
New
South
Wales
Health
Grants
Round
(SGT).
Nature,
Год журнала:
2023,
Номер
621(7979), С. 592 - 601
Опубликована: Авг. 30, 2023
Abstract
Currently
circulating
SARS-CoV-2
variants
have
acquired
convergent
mutations
at
hot
spots
in
the
receptor-binding
domain
1
(RBD)
of
spike
protein.
The
effects
these
on
viral
infection
and
transmission
efficacy
vaccines
therapies
remains
poorly
understood.
Here
we
demonstrate
that
recently
emerged
BQ.1.1
XBB.1.5
bind
host
ACE2
with
high
affinity
promote
membrane
fusion
more
efficiently
than
earlier
Omicron
variants.
Structures
BQ.1.1,
XBB.1
BN.1
RBDs
bound
to
fragment
antigen-binding
region
S309
antibody
(the
parent
for
sotrovimab)
human
explain
preservation
binding
through
conformational
selection,
altered
recognition
immune
evasion.
We
show
sotrovimab
binds
avidly
all
variants,
promotes
Fc-dependent
effector
functions
protects
mice
challenged
hamsters
XBB.1.5.
Vaccine-elicited
plasma
antibodies
cross-react
trigger
against
current
despite
a
reduced
neutralizing
activity,
suggesting
mechanism
protection
disease,
exemplified
by
S309.
Cross-reactive
RBD-directed
memory
B
cells
remained
dominant
even
after
two
exposures
spikes,
underscoring
role
persistent
imprinting.
Nature Communications,
Год журнала:
2022,
Номер
13(1)
Опубликована: Окт. 29, 2022
Abstract
The
latest
SARS-CoV-2
variant
of
concern
Omicron,
with
its
immune
escape
from
therapeutic
anti-Spike
monoclonal
antibodies
and
WA-1
vaccine-elicited
sera,
demonstrates
the
continued
relevance
COVID-19
convalescent
plasma
(CCP)
therapies.
Lessons
learnt
previous
usage
CCP
suggests
focusing
on
early
outpatients
immunocompromised
recipients,
high
neutralizing
antibody
titer
units.
Here,
we
systematically
review
Omicron-neutralizing
activity
data,
report
that
approximately
47%
(424/902)
samples
unvaccinated
pre-Omicron
donors
neutralizes
Omicron
BA.1
a
very
low
geometric
mean
titers
for
50%
neutralization
GM(GMT
50
)
~13,
representing
>
20-fold
reduction
neutralization.
Non-convalescent
subjects
who
had
received
two
doses
mRNA
vaccines
GM(GMT50)
~27.
However,
vaccinees
recovering
either
variants
infection,
or
third-dose
uninfected
was
nearly
100%
against
BA.1,
BA.2
BA.4/5
GM(GMT(
))
all
over
189,
10
times
higher
than
CCP.
Fully
vaccinated
post-BA.1
(Vax-CCP)
450
>1,500
BA.2.
These
findings
have
implications
both
stocks
collected
in
prior
pandemic
periods
future
plans
to
restart
collections.
Thus,
Vax-CCP
provides
an
effective
tool
combat
ongoing
antibodies.
Nature Communications,
Год журнала:
2022,
Номер
13(1)
Опубликована: Дек. 13, 2022
Several
studies
have
shown
that
SARS-CoV-2
BA.1
omicron
is
an
immune
escape
variant.
Meanwhile,
however,
BA.2
and
BA.5
became
dominant
in
many
countries
replaced
BA.1.
As
both
several
mutations
compared
to
BA.1,
we
analyzed
whether
show
further
relative
Here,
characterized
neutralization
profiles
against
the
sub-variants
plasma
samples
from
individuals
with
different
history
of
exposures
infection/vaccination
found
unvaccinated
after
a
single
exposure
had
limited
cross-neutralizing
antibodies
pre-omicron
variants
Consequently,
our
antigenic
map
including
all
Variants
Concern
sub-variants,
showed
are
distinct
variants,
but
three
also
antigenically
each
other.
The
antibody
landscapes
illustrate
current
space,
as
described
maps,
generated
only
or
more
close
two
distant
variants.
describe
space
inhabited
by
relevant
understanding
which
will
important
implications
for
vaccine
strain
adaptations.
Science Immunology,
Год журнала:
2022,
Номер
7(78)
Опубликована: Ноя. 10, 2022
Numerous
safe
and
effective
coronavirus
disease
2019
vaccines
have
been
developed
worldwide
that
use
various
delivery
technologies
engineering
strategies.
We
show
here
containing
prefusion-stabilizing
S
mutations
elicit
antibody
responses
in
humans
with
enhanced
recognition
of
the
Immunity,
Год журнала:
2024,
Номер
57(4), С. 904 - 911.e4
Опубликована: Март 14, 2024
Immune
imprinting
describes
how
the
first
exposure
to
a
virus
shapes
immunological
outcomes
of
subsequent
exposures
antigenically
related
strains.
Severe
acute
respiratory
syndrome
coronavirus-2
(SARS-CoV-2)
Omicron
breakthrough
infections
and
bivalent
COVID-19
vaccination
primarily
recall
cross-reactive
memory
B
cells
induced
by
prior
Wuhan-Hu-1
spike
mRNA
rather
than
priming
Omicron-specific
naive
cells.
These
findings
indicate
that
immune
occurs
after
repeated
exposures,
but
whether
it
can
be
overcome
remains
unclear.
To
understand
persistence
imprinting,
we
investigated
plasma
antibody
responses
administration
updated
XBB.1.5
vaccine
booster.
We
showed
booster
elicited
neutralizing
against
current
variants
were
dominated
pre-existing
previously
spike.
Therefore,
persists
multiple
spikes
through
infection,
including
post
vaccination,
which
will
need
considered
guide
future
vaccination.
Frontiers in Immunology,
Год журнала:
2023,
Номер
14
Опубликована: Май 23, 2023
The
highly
transmissible
Omicron
(B.1.1.529)
variant
of
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
was
first
detected
in
late
2021.
Initial
waves
were
primarily
made
up
sub-lineages
BA.1
and/or
BA.2,
BA.4,
and
BA.5
subsequently
became
dominant
mid-2022,
several
descendants
these
have
since
emerged.
infections
generally
caused
less
disease
on
average
than
those
by
earlier
variants
concern
healthy
adult
populations,
at
least,
part,
due
to
increased
population
immunity.
Nevertheless,
healthcare
systems
many
countries,
particularly
with
low
immunity,
been
overwhelmed
unprecedented
surges
prevalence
during
waves.
Pediatric
admissions
also
higher
compared
previous
concern.
All
exhibit
partial
escape
from
wild-type
(Wuhan-Hu
1)
spike-based
vaccine-elicited
neutralizing
antibodies,
more
enhanced
immuno-evasive
properties
emerging
over
time.
Evaluating
vaccine
effectiveness
(VE)
against
has
become
challenging
a
complex
background
varying
coverage,
platforms,
prior
infection
rates,
hybrid
Original
messenger
RNA
booster
doses
substantially
improved
VE
or
BA.2
symptomatic
disease.
However,
protection
waned,
reductions
months
after
administration.
While
original
CD8
+
CD4
T-cell
responses
cross-recognize
sub-lineages,
thereby
retaining
outcomes,
variant-adapted
vaccines
are
required
expand
the
breadth
B-cell
improve
durability
protection.
Variant-adapted
rolled
out
2022
increase
overall
antigenically
aligned
immune
mechanisms.